Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

CA14161Y2006
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00M0GNP68
CRDL
Cardiol Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Cardiol Therapeutics Inc
ISIN
CA14161Y2006
TICKER
CRDL
MIC
XTSX
REUTERS
CRDL.TO
BLOOMBERG
CRDL CN
Wed, 28.09.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - September 28, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular diseases ("CVD"), announced today t...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.08.2022       Cardiol Therapeutics
CA14161Y2006

Multi-center, international, double-blind, randomized, placebo-controlled trial to enroll 100 patientsOakville, Ontario--(Newsfile Corp. - August 3, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an a...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.06.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 29, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), announ...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.06.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 27, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), is ple...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.06.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 9, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular disease, is pleased to announce that it h...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.05.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - May 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that its...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.05.2022       Cardiol Therapeutics
CA14161Y2006

Third IND authorization for CardiolRx™ in cardiovascular diseaseStudy to run in parallel with Company's multi-national Phase II acute myocarditis trial, expected to commence imminently CardiolRx™ is now eligible for orphan drug status in two indicationsOakville, Ontario--(Newsfile Corp. - May 17, 2022) - Cardiol Therapeutics Inc. (NASDA...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.03.2022       Cardiol Therapeutics
CA14161Y2006

Expanded the Phase II/III LANCER clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are hospitalized with COVID-19Received authorization from the FDA to proceed with the Company's IND to commence a Phase II multi-national clinical trial in patients with acute myocarditisMade strategic appointments to...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.03.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - March 22, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that Cardiol's Chief Medical Off...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.03.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - March 15, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease ("CVD"), is pleased to announce that its Board of...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 01.03.2022       Cardiol Therapeutics
CA14161Y2006

LANCER Trial expanded to include up to 20 Additional Clinical Research CentersOakville, Ontario--(Newsfile Corp. - March 1, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatmen...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.01.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - January 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, today announced the appointment of Paul M. Rid...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.11.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - November 5, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for the treatment of cardiovascular disease, announced today the closing of its previously announced public offering (the...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 25.10.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - October 25, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that it has received approval from Health...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 18.10.2021       Cardiol Therapeutics
CA14161Y2006

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular diseaseOakville, Ontario--(Newsfile Corp. - October 18, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage bi...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.09.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - September 16, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it will present at the 2021 Cantor Virtual...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.09.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - September 10, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announces the acceleration of the expiry date of all outstandin...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.09.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - September 7, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce the appointment of Michael J. Willner, Es...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.08.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - August 24, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that the U.S. Food and Drug Administration...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.08.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - August 9, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it has received final approval from The Nasdaq Capital Market...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 07.07.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - July 7, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today announced that its Board of Directors has appointed...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.06.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 30, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announces results from its Annual General and Special Me...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.06.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 28, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that the Company's virtual Annual...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.05.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - May 12, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce the closing of its previously announced "bought deal" short f...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 28.04.2021       Cardiol Therapeutics
CA14161Y2006

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular diseaseOakville, Ontario--(Newsfile Corp. - April 28, 2021) -  Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a cli...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.04.2021       Cardiol Therapeutics
CA14161Y2006

Results expected to support the Company's plans to file an IND application with the FDA for a Phase II international trial in acute myocarditisOakville, Ontario--(Newsfile Corp. - April 12, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developi...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 01.04.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - April 1, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today filed its audited Financial Statements and Managem...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 30.03.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - March 30, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today announced that Dr. Andrew Hamer has joined the Com...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.03.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - Dienstag, 2. März 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" oder das "Unternehmen"), ein Biotechnologieunternehmen im klinischen Stadium mit Fokus auf der Entwicklung innovativer entzündungshemmender Therapien zur Behandlung von Herz-Kreislauf-Erkrankungen gab heute...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.03.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - March 2, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it has submitted an application to u...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.01.2021       Cardiol Therapeutics
CA14161Y2006

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular diseaseOakville, Ontario--(Newsfile Corp. - January 21, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage bi...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.01.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - January 7, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, announced today that David Elsley, President and CEO of Cardiol, will participate in the followin...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.12.2020       Cardiol Therapeutics
CA14161Y2006

Study results are expected to support the Company's plans to file an IND application with the FDA for a Phase II clinical trial in acute myocarditisOakville, Ontario--(Newsfile Corp. - December 22, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.12.2020       Cardiol Therapeutics
CA14161Y2006

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease now being initiated at clinical centers in the United StatesOakville, Ontario--(Newsfile Corp. - December 15, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OT...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 20.10.2020       Cardiol Therapeutics
CA14161Y2006

The first pharmaceutically produced THC-free* extra-strength cannabidiol (CBD)Oakville, Ontario--(Newsfile Corp. - October 20, 2020) -  Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, is pleased t...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.09.2020       Cardiol Therapeutics
CA14161Y2006

Redondo Beach, California--(Newsfile Corp. - September 30, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering a potentially major development in the quest to improve outcomes for COVID-19 patients. The US Food and Drug Adminis...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 25.09.2020       Cardiol Therapeutics
CA14161Y2006

Trial will take place at major U.S. centers and examine the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease (CVD)Oakville, Ontario--(Newsfile Corp. - September 25, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or t...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 16.09.2020       Cardiol Therapeutics
CA14161Y2006

Redondo Beach, California--(Newsfile Corp. - September 16, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering Cardiol Therapeutics Inc.'s (TSX: CRDL) (OTCQX: CRTPF) initiation of a Phase 1 clinical study, intended to assess t...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.09.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - September 15, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular diseases, including heart failure and acute myocarditis, announces that Cardiol's President and CEO,...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.08.2020       Cardiol Therapeutics
CA14161Y2006

Study Designed to Support Cardiol Therapeutics' Phase 2 International Trial in Acute MyocarditisOakville, Ontario--(Newsfile Corp. - August 26, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular disease...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.08.2020       Cardiol Therapeutics
CA14161Y2006

Redondo Beach, California--(Newsfile Corp. - August 5, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing how the past success of the orphan drug designation informs Cardiol Therapeutics Inc.'s (TSX: CRDL) (OTCQX: CRTPF) eff...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.07.2020       Cardiol Therapeutics
CA14161Y2006

Redondo Beach, California--(Newsfile Corp. - July 15, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing the connection between heart disease, COVID-19, and inflammation. Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF),...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 29.06.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 29, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it has appointed Steven Grasso as Business A...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 25.06.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 25, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), today announced that David Elsley, President and CEO of Cardiol, has filed an early warning report (the "Report") in respect of his ownership of class A common shares of the Company (the "Shares") under the Comp...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.06.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 4, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce the closing of its previously announced "bought deal" short form pro...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.06.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 2, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, announces results from its Annual General Meeting ("AGM") of shareholders h...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - May 29, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it will webcast the Company's virtual Annua...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.05.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - May 14, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it has entered into an agreement with a syn...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.05.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - May 13, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it has entered into an agreement with Canaccord...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.05.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - May 6, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce the filing of a new patent application covering the us...
Read more
Cardiol Therapeutics
Technical Analysis Termsheets Terminal
Permalink